cagrilintide and semaglutide New in the August 14, 2025, issue of NEJM: ⁣ ⁣ Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial)⁣ ⁣ Cagrilintide– for Overweight Diabetes (REDEFINE 2 phase 3a trial)⁣ ⁣ Cagrilintide vs retatrutide: amylin analogue

They can support energy metabolism and fat transport, especially in individuals with low B12 or metabolic sluggishness

While the study was observational (meaning that causality cant be confirmed), it does add to the growing body of evidence suggesting that its worth investigating these weight-loss drugs as potential cancer prevention tools, says lead author, Professor Elizabeth McDonald

I do think it raises some interesting questions about the tools that are available to people in pursuit of a particular body type, rather than in pursuit of some version of health, Soloman said

Anxiety afflicts 2545% of chronic liver disease patients, while depression affects a staggering 2972% (41)

Neuroscience 122:10731080